Namsos

Amyotrophic lateral sclerosis (ALS) is a serious, fast-progressing nervous system disease with an average survival of 2.5 years after diagnosis. Currently, effective treatments are limited to Riluzole. Research suggests that increasing cell access to Nicotinamide Adenine Dinucleotide (NAD) and stimulating enzymes called sirtuins may slow disease progression. This study aims to evaluate whether a combination of Nicotinamide Riboside (NR) and Pterostilbene, called EH301, can slow neurodegeneration, delay disease progression, improve survival, and enhance quality of life in ALS patients. The NO-ALS extension study follows patients who completed the original NO-ALS trial. All participants receive the active treatment EH301, which combines Nicotinamide Riboside and Pterostilbene, as an open-label extension. This study provides patients the option for compassionate use of the supplement while assessing its effects on motor symptoms, lung function, and survival. Participants will be monitored for adverse events throughout the study, which lasts up to 1 year. Researchers will track safety, progression of motor symptoms, changes in vital capacity, and overall survival. This extension allows long-term observation of EH301's impact on ALS progression and patient well-being.

The BAROBS project is a collaberation between three public hospitals in Norway exploring the concequeces ten years or more after undergoing gastric bypass or sleeve gastrectomy for severe obesity. 1400 patients who underwent bariatric surgery at the three hospitals will be invited to a follow up including antrophometric, meassurment of bodily composition by bioimpedance and DXA, blood samples, questionnaires on sosioeconomic topics, symptoms and quality of life, continous glucose monitoring, dental examination, and other clinical evaluation.

Researchers are evaluating the Invest in Play (iiP) parent program to see if it can reduce problem behaviors in children and improve parenting practices. The study focuses on families with children who show challenging behaviors, aiming to find out if the iiP program leads to better outcomes for both children and parents by comparing it to a control group. This is a behavioral intervention study involving children with problem behavior and attention deficit and disruptive behavior disorders. The intervention involves a 12-session group-based parent program called Invest in Play (iiP), led by two trained group leaders. Families are randomly assigned to either the iiP program group or a control group. The program is designed to support parents in managing their children's behaviors through structured group sessions. Participants will complete surveys before starting the program and after finishing it to measure changes in children's behaviors. The main outcome measured is the change in the Eyberg Child Behavior Inventory (ECBI) score from the beginning to the end of the 12-week treatment period. The study tracks these changes to assess if the iiP program effectively reduces problem behaviors in children.

Researchers are investigating the genetic factors that may contribute to the development of Amyotrophic Lateral Sclerosis (ALS) in Norway. The study aims to better understand genetic causes relevant to ALS by analyzing gene frequencies, new ALS genes, and genetic risk factors from 2020 through 2030. Participants will provide written informed consent and complete a brief questionnaire about their family history. A blood sample will be collected for genetic analysis, which is carried out at the Department of Medical Genetics, Telemark Hospital Trust throughout the recruitment period. Participants may opt to receive their genetic results in a diagnostic setting. During the study, participants will be involved in providing clinical information, completing questionnaires, and submitting blood samples. Researchers will monitor genetic characteristics and analyze data related to gene frequency and new ALS genes over time. The study includes adults aged 16 to 100 years and involves continuous genetic analysis from 2020 to 2030.

This research aims to investigate how personalized exercise programs affect dynamic balance and physical function in adults with rare neuromuscular disorders including Charcot-Marie-Tooth disease, Facioscapulohumeral Muscular Dystrophy, and Myotonic Dystrophy Type 1. The study compares the effects of personalized exercise treatment against regular follow-up care. It is a national, multi-center study involving 120 participants from Norway's four health regions. Participants in the intervention group will undergo a personalized exercise program consisting of two 12-day sessions at a rehabilitation center separated by a three-month digital exercise period. The control group will receive usual care involving hospital and community health system appointments based on individual recommendations. This approach aims to evaluate physical function improvements through a structured and tailored exercise regimen. During the study, participants' dynamic balance will be assessed at the start, after four months, and, for the intervention group, also at 10 and 16 months using the Mini-Balance Evaluation Systems Test (Mini-BESTest). Researchers will also monitor physical activity levels, body composition, motor unit estimates, muscle characteristics, metabolomics, health indicators, and quality of life. The study includes long-term follow-up to measure sustained benefits and safety.